Fudan University affiliated Huashan Hospital
Welcome,         Profile    Billing    Logout  
 44 Trials 
116 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zhang, Wenhong
HS-10234-401, NCT06743438: Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB

Active, not recruiting
4
640
RoW
Tenofovir Amibufenamide（TMF）, HS-10234
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Hepatitis B, Chronic
06/24
09/29
TB-TRUST, NCT03867136: Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)

Completed
4
354
RoW
PZA sensitivity guided ultra-short all Oral Regimen, Standardized Shorter Regimen
Huashan Hospital
Multidrug Resistant Tuberculosis
08/24
08/24
NCT04201808: Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides

Recruiting
4
100
RoW
Tenofovir Alafenamide 25 MG, Vemlidy
New Discovery LLC, Beijing Ditan Hospital
Hepatitis B, Chronic
09/23
09/23
SWIFT, NCT06153069: Subclinical TB With Innovative Modified Short-course Regimens

Active, not recruiting
4
556
RoW
Short-course regimen, Standard regimen
Huashan Hospital
Tuberculosis
10/25
11/27
NCT05279235: Efficacy and Safety of JT001 (VV116) Compared With Favipiravir

Terminated
3
290
RoW
JT001, VV116, JT001 placebo, VV116 placebo, Favipiravir, Favipiravir placebo
Shanghai Vinnerna Biosciences Co., Ltd., Sponsor GmbH
Moderate to Severe COVID-19
12/22
12/22
CURE-SepSIRS, NCT05391789: Clinical Efficacy of Ulinastatin for Treatment of Sepsis With Systemic Inflammatory Response Syndrome

Not yet recruiting
3
120
RoW
Ulinastatin, Treatment, Placebo, Control
Huashan Hospital
Sepsis
06/23
12/23
ZX-7101A-207, NCT06099873: Study to Assess the Safety and Efficacy of ZX-7101A in Adolescents with Influenza

Completed
3
361
RoW
ZX-7101A, Placebo
Nanjing Zenshine Pharmaceuticals
Respiratory Viral Infection
02/25
02/25
INSPIRE-TB, NCT05081401: Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis

Recruiting
3
1050
RoW
Bdq(Lzd)+Lfx(Mfx)+Cfz(Cs)+Pto+E+H+Z, A1, A2a, A2b, A2c, A3, A4, A5, B-SOC, B1
Huashan Hospital
Multidrug Resistant Tuberculosis, Rifampicin Resistant Tuberculosis, Pre-XDR-TB
12/26
12/27
TB-YOUTH, NCT06022146: TB YOUTH - TB SYstemic Management Using One-month, Ultra-short TPT Regimen for ScHool Contacts

Recruiting
3
2978
RoW
Rifampin and Isoniazid, isoniazid and rifapentine
Huashan Hospital
Tuberculosis, Latent Tuberculosis
09/26
09/26
INSPIRE-CODA, NCT06081361: Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

Active, not recruiting
3
186
RoW
Bedaquiline, BDQ, Delamanid, DLM, Contezolid, CZD, Levofloxacin, LFX, Moxifloxacin, MFX, Clofazimine, CFZ, Linezolid, LZD, Cycloserine, CS, Prothionamide, Pto, Pyrazinamide, PZA, Para-Aminosalicylic Acid, PAS, Ethambutol, EMB
Beijing Chest Hospital, National Medical Center for Infectious Diseases
Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
10/26
12/26
NCT05242042: JT001 (VV116) for the Early Treatment of COVID-19

Terminated
2/3
381
RoW
JT001, VV116, Placebo
Shanghai JunTop Biosciences Co., LTD, Sponsor GmbH
Mild to Moderate COVID-19
03/23
03/23
ORIENT, NCT05401071: Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)

Recruiting
2/3
2442
RoW
Short Regimen with Rifapentine 10mg/kg, Standardized Regimen, Short Regimen with Rifapentine 15mg/kg, Short Regimen with Rifapentine 20mg/kg
Huashan Hospital
Tuberculosis, Pulmonary
10/24
11/27
NCT05445934: Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)

Recruiting
2/3
1188
RoW
FB2001, DC402234, FB2001 placebo
Frontier Biotechnologies Inc.
COVID-19
11/23
12/23
B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Recruiting
2
280
Europe, Canada, Japan, US, RoW
Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo
GlaxoSmithKline
Chronic Hepatitis B Virus Infection, Hepatitis B
10/27
10/27
NCT05217732: Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers

Completed
1
66
RoW
ZX-7101A, Placebo
Nanjing Zenshine Pharmaceuticals
Safety Issues, Tolerance, Pharmacokinetics, Food Effect
08/22
12/22
NCT04883177: Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101)

Completed
N/A
1000
RoW
Hepatopancreatobiliary Surgery Institute of Gansu Province, LanZhou University, Huashan Hospital, The Sixth People's Hospital of Shenyang City, Xingtai City People's Hospital, Jinchang Central Hospital, Baoding People's Hospital, The Third People's Hospital of Zhenjiang City, Shanxi Bethune Hospital, Wuhan Jinyintan Hospital, Jincheng People's Hospital, The Third People's Hospital of Tibet Autonomous Region, People's Hospital of Ningxia Hui Autonomous Region, Fuling Central Hospital of Chongqing City, Hospital of the Chengdu Office of the People's Government of Tibet Autonomous Region, The Central Hospital of Lishui City, The Third People's Hospital of Linfen City, Yibin First People's Hospital, Jingzhou Central Hospital, Wuxi Fifth People's Hospital, Qingyang People's Hospital, The First Affiliated Hospital of Anhui Medical University, Beilun Hospital of Traditional Chinese Medicine, Henan Provincial People's Hospital, Qingdao Sixth People's Hospital, The First Affiliated Hospital of Xiamen University, Shandong Provincial Hospital, Beijing YouAn Hospital, The First People's Hospital of Taicang, The Third People's Hospital of Taiyuan, Tianjin Second People's Hospital, Tianjin Third Central Hospital, Qishan Hospital of Yantai City, Affiliated Hospital of Yunnan University, The First People's Hospital of Yunnan, The Fourth Affiliated Hospital of Zhejiang University, Third Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital of Chongqing Medical University
COVID-19, Liver Disease, Vaccine Reaction
01/22
05/22
AI-MIRID, NCT06553911: Exploring the Application Efficacy of Artificial Intelligence (AI) Diagnostic Tools in Medical Imaging (MI) of Respiratory(R) Infectious (I) Disease (D)

Recruiting
N/A
2000
RoW
Artificial Intelligence-based medical imaging interpretation
Huashan Hospital
Respiratory Infectious Diseases, Artificial Intelligence, Medical Imaging
12/25
12/26
NMCIDCHESS2201, NCT05204602: Safety and Immunogenicity of COVID-19 Vaccine Booster in Patients With Liver Diseases

Recruiting
N/A
1000
RoW
Huashan Hospital, LanZhou University, Xingtai People's Hospital, The Third Central Hospital of Tianjin, The Third People's Hospital of Taiyuan, Lishui Country People's Hospital, Baoding People's Hospital, The Affiliated Hospital of Qingdao University, Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine, The Fifth People's Hospital of Wuxi, Jincheng People's Hospital, The Sixth Peoples Hospital of Shenyang, Zhenjiang Third Hospital, The Third People's Hospital of Linfen City, The First Affiliated Hospital of Dalian Medical University, The Fourth People's Hospital of Qinghai Province, The Third People's Hospital of Tibet Autonomous Region, The Second Affiliated Hospital of Chongqing Medical University, Peking University Health Science Center, The Affiliated Hospital Of Southwest Medical University
COVID-19, Vaccine Reaction, Liver Diseases
08/22
12/22
TB-TRUSTplus, NCT04717908: Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS

Completed
N/A
89
RoW
Bedaquiline, BDQ, Pyrazinamide, PZA, Linezolid, LZD, Cycloserine, Cs, Clofazimine, CFZ
Huashan Hospital
Multidrug Resistant Tuberculosis
06/24
06/24
STAT, NCT05906459: Simplification and Test and Treat Strategies Towards Hepatitis C Eliminationplatform" in China

Recruiting
N/A
20000
RoW
Anti-HCV antibody and HCV core antigen testing
Huashan Hospital
Hepatitis C Virus Infection
12/23
06/24
NCT05855395: The Standard of Care Combined With Glucocorticoid in Elderly People With Mild or Moderate COVID-19

Recruiting
N/A
5815
RoW
Glucocorticoid, dexamethasone, prednisone, methylprednisolone
Huashan Hospital
COVID-19
05/24
12/24
NCT04020536: Real World Study of Classic Infectious Disease

Recruiting
N/A
10000
RoW
Antibiotics
Huashan Hospital, First Affiliated Hospital of Xinjiang Medical University, First Affiliated Hospital of Harbin Medical University, The ninth Hospital of NanChang city, Luoyang Central Hospital, Second Affiliated Hospital of Nanchang University, The Fifth Affiliated Hospital Xinjiang Medical University, LanZhou University, Huizhou Municipal Central Hospital, First Affiliated Hospital of Fujian Medical University, Fuzhou Municipal Infectious Diseases Hospital, Henan Provincial People's Hospital, The First Affiliated Hospital of Lanzhou Medical University, Linyi People's Hospital, Nantong University, Nanyang Central Hospital, Qilu Hospital of Shandong University, Qianfoshan Hospital, Infectious Hospital of Jining City, The Affiliated Hospital of Jining Medical University and Zaozhuang City, The First Affiliated Hospital of Shanxi Medical University, First Affiliated Hospital Xi'an Jiaotong University, People's Hospital of Xinjiang Uygur Autonomous Region, Yuncheng Central Hospital, Zibo Central Hospital, The Second Affiliated Hospital of Henan Medical University, West Hospital of the First Affiliated Hospital of Guangxi University, First Affiliated Hospital of Jilin University, The Affiliated Hospital of Xuzhou Medical University, The First Affiliated Hospital with Nanjing Medical University, The First Affiliated Hospital of Anhui Medical University, The Second Hospital of Shandong University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Brucelloses, Epidemic Hemorrhagic Fever, Kala-Azar
06/24
06/29
NCT04025944: Real World Study of Chronic Viral Hepatitis

Recruiting
N/A
10000
RoW
Huashan Hospital
Hepatitis, Chronic
08/24
08/29
GRACE-TB, NCT03604848: NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB

Not yet recruiting
N/A
488
RoW
WHO-approved MDR-TB regimen, NGS-guided regimen: Regimen A, NGS-guided regimen: Regimen B, NGS-guided regimen: Regimen C
Huashan Hospital
Multidrug Resistant Tuberculosis
08/24
08/24
ESAR, NCT04955756: Early Identification and Severity Prediction of Acute Respiratory Infectious Disease

Recruiting
N/A
440
RoW
mNGS, Multiplex PCR
Huashan Hospital
Acute Respiratory Infection, Severe Pneumonia, Next Generation Sequencing, Multiplex PCR
12/24
12/24
NCT05912010: A Study on Pathogenic Surveillance and Nasopharyngeal Carriage of Children and Adolescents Based on Hospitals and Communities in Hainan Province

Recruiting
N/A
6000
RoW
NP/OP swab
Huashan Hospital
Pneumonia
12/24
12/24
RISE, NCT06597682: Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction

Not yet recruiting
N/A
632
RoW
Prednisone, Budesonide/Formoterol, Vitamin C combined with Coenzyme Q10 oral treatment, Montelukast tablets oral treatment
Huashan Hospital
Post-acute Sequelae of SARS-COV-2 Infection
07/27
07/27
NCT06923280: Sequential PEG-IFN for HBV After Ending RNA-targeted Regimens

Not yet recruiting
N/A
30
RoW
Pegylated Interferon-alpha (IFN)
Huashan Hospital
Hepatitis B, Chronic
12/27
05/28
NCT06033807: Active Screening of Latent Tuberculosis Infection in School Contacts of Active Tuberculosis Patients

Recruiting
N/A
31440
RoW
QuantiFERON-TB Gold (QFT) test, Chest CT Scan, Chest X-ray Scan, Sputum Culture, Sputum Xpert MTB/RIF
Huashan Hospital, Guizhou Center for Disease Control and Prevention
Tuberculosis, Latent Tuberculosis Infection
09/25
12/25
NCT05937178: Real-world Study Optimizing Nucleotide-analogues

Recruiting
N/A
20000
RoW
ETV/TAF/TDF/TMF/IFN, ETV/TAF/TDF/TMF
Huashan Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, Beijing YouAn Hospital, Peking University People's Hospital, Peking University First Hospital, Xiamen Hospital of Traditional Chinese Medicine, First Affiliated Hospital of Fujian Medical University, LanZhou University, Third Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, The Affiliated Hospital Of Guizhou Medical University, Hainan General Hospital, Hebei Medical University Third Hospital, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Henan Provincial People's Hospital, The Second Affiliated Hospital of Harbin Medical University, Tongji Hospital, Wuhan Union Hospital, China, Renmin Hospital of Wuhan University, Central South University, Xiangya Hospital of Central South University, The First Hospital of Jilin University, the Second Hospital of Nangjing, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Hospital of Xuzhou Medical University, The First Affiliated Hospital of Nanchang University, Shengjing Hospital, Qingdao Sixth People's Hospital, Shandong Provincial Hospital Affiliated to Shandong First Medical University, The Second Hospital of Shandong University, The First Affiliated Hospital of Shanxi Medical University, Tang-Du Hospital, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, West China Hospital, Tianjin Second People's Hospital, First Affiliated Hospital of Xinjiang Medical University, The First People's Hospital of Yunnan, Shulan (Hangzhou) Hospital, Zhejiang University, Southwest Hospital, China, The Second Affiliated Hospital of Chongqing Medical University, Sichuan Provincial People's Hospital
Hepatitis B, Chronic
01/29
01/29
NCT05965388: Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy

Not yet recruiting
N/A
5000
RoW
nucleoside analogues or interferon
Wen-hong Zhang, Shandong Provincial Hospital Affiliated to Shandong First Medical University, First Affiliated Hospital Xi'an Jiaotong University, The Affiliated Hospital of Xuzhou Medical University, First Affiliated Hospital of Fujian Medical University, The Third People's Hospital of Taiyuan, The First People's Hospital of Yunnan, The First Affiliated Hospital of Anhui Medical University, Wuhan Union Hospital, China, The First Affiliated Hospital with Nanjing Medical University
HBV, HCC
02/29
02/29
TCCT, NCT04484129: MDR-TB Close Contacts Tracing in China ( Study)

Not yet recruiting
N/A
500
RoW
Huashan Hospital
Multidrug Resistant Tuberculosis
12/22
12/22
NCT05493917: A Real-world Study to Evaluate the Safety and Immunogenicity of a Third-dose Booster After Two Doses of an Inactivated COVID-19 Vaccine

Recruiting
N/A
2000
RoW
an inactivated SARS-CoV-2 vaccine named BBIBP-CorV
Huashan Hospital
COVID-19, Vaccine Reaction
12/22
12/22
OASIS, NCT04896255: Long-term Outcomes of Anti-viral Therapies in Patients With Chronic Viral Hepatitis B

Recruiting
N/A
20000
RoW
peginterferon alpha based regimen, nucleos(t)ide
Huashan Hospital, Chinese Foundation for Hepatitis Prevention and Control, Taiyuan No.3 Hospital, First Affiliated Hospital of Chongqing Medical University, Beijing YouAn Hospital, Henan Provincial People's Hospital, Yunnan Provincial No.1 Hospital, Third Affiliated Hospital, Sun Yat-Sen University, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of Xiamen University, Beijing Ditan Hospital, Tianjing No.2 People's Hospital, Qingdao No.6 People's Hospital, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Ningbo Beilun District Traditional Chinese Medicine Hospital, Wuxi No.5 People's Hospital, Taicang No.1 People's hospital, First Affiliated Hospital Xi'an Jiaotong University
Chronic Hepatitis b
07/25
07/30
Zhang, Jing
NCT05536726: A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants with Moderate-to-Severe Plaque Psoriasis

Completed
3
458
RoW
608 Q2W, 608 Q4W, Placebo, PBO
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Psoriasis
10/23
06/24
NCT05213507: Inhaled Amikacin in Preventing AECOPD

Not yet recruiting
3
136
RoW
aerosol inhaled Amikacin Sulfate Injection, Aerosol Inhaled investigation drug, conventional therapy, Comparison Group
Shanghai Zhongshan Hospital
COPD, COPD Exacerbation
12/23
12/23
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Recruiting
3
522
RoW
D-1553 Tablet, Docetaxel injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non Small Cell Lung Cancer
10/26
12/27
ReNEW, NCT06373731: Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

Recruiting
3
360
Europe, US, RoW
Elamipretide, Elamipretide HCL, Placebo
Stealth BioTherapeutics Inc.
Age Related Macular Degeneration (ARMD)
08/26
08/27
ZX-7101A-207, NCT06099873: Study to Assess the Safety and Efficacy of ZX-7101A in Adolescents with Influenza

Completed
3
361
RoW
ZX-7101A, Placebo
Nanjing Zenshine Pharmaceuticals
Respiratory Viral Infection
02/25
02/25
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NAC Attack, NCT05537220: Oral N-acetylcysteine for Retinitis Pigmentosa

Recruiting
3
438
Europe, Canada, US, RoW
N-acetylcysteine, Placebo
Johns Hopkins University, National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Centro Medico ABC, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania
Retinitis Pigmentosa
12/28
12/28
NCT06569524: Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)

Recruiting
2
120
RoW
TQA2225/AP025 or TQA2225/AP025 Placebo 25mg, TQA2225/AP025 or TQA2225/AP025 Placebo 50mg
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Non-alcoholic Steatohepatitis
12/26
12/27
PRO-CHASE, NCT05419193: PROpranolol for Cerebral Hemorrhage-ASsociated pnEumonia

Completed
2
168
RoW
Propranolol Hydrochloride, control group
Beijing Tiantan Hospital
Stroke, Vascular Accident, Intracranial Hemorrhages, Intracerebral Hemorrhage, Hemorrhagic Stroke, Stroke, Acute
12/24
03/25
TEASE, NCT02402660: Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Enrolling by invitation
2
160
US
ALK-001, C20-D3-Retinyl Acetate, C20 Deuterated vitamin A, Placebo
Alkeus Pharmaceuticals, Inc.
Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
06/26
11/26
NCT05328531: Clinical Study of Genakumab for Injection in Patients With Acute Gout

Completed
1/2
121
RoW
Genakumab for Injection, Placebo for Genakumab for Injection
Changchun GeneScience Pharmaceutical Co., Ltd., Huashan Hospital, Hainan General Hospital, Linyi People's Hospital, The Second Affiliated Hospital of Chongqing Medical University, Changhai Hospital, The First Affiliated Hospital with Nanjing Medical University, Shengjing Hospital, Affiliated Hospital of Nantong University
Acute Gout
06/22
06/22
NCT06302374: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults

Completed
1/2
202
RoW
GR2001, Placebo, HTIG, Tetanus Toxoid
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Tetanus
11/23
02/24
NCT04434482: IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer

Completed
1/2
59
US, RoW
IMP4297(senaparib), temozolomide
Impact Therapeutics, Inc.
Advanced Solid Tumours, Small Cell Lung Cancer
04/24
04/24
NCT04361812: Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection

Not yet recruiting
1
60
RoW
HS632, Recombinant anti IgE humanized monoclonal antibody 150mg, Omalizumab (Xolair®), Omalizumab 150mg
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd
Similarity of Pharmacokinetics and Safety
12/21
12/21
NCT05280483: ABSK021 Food Effect Study in Healthy Subjects

Completed
1
16
RoW
ABSK021 with fed state, ABSK021 with fasted state
Abbisko Therapeutics Co, Ltd
Neoplasms
08/22
05/23
NCT04880512: The Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy Subjects

Recruiting
1
102
RoW
SYHX 1901 tablets, Placebo
CSPC Ouyi Pharmaceutical Co., Ltd.
Healthy Subjects
08/22
12/22
NCT05217732: Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers

Completed
1
66
RoW
ZX-7101A, Placebo
Nanjing Zenshine Pharmaceuticals
Safety Issues, Tolerance, Pharmacokinetics, Food Effect
08/22
12/22
NCT05490316: A Study of IBI353 (Orismilast) in Chinese Healthy Adults

Completed
1
20
RoW
IBI353 (Orismilast), placebo
Innovent Biologics (Suzhou) Co. Ltd.
Healthy Subjects
11/22
12/22
NCT04994912: First in Human Study of EI-001 Monoclonal Antibody in Healthy Volunteers

Recruiting
1
36
RoW
EI-001, Placebo
Elixiron Immunotherapeutics Limited
Healthy
02/25
04/25
NCT05750355: Evaluate the Effect of TPN171H on the QT/QTc Interval in Healthy Volunteers

Completed
1
32
RoW
TPN171H 10 mg Group, TPN171H 10 mg, TPN171H 30 mg Group, TPN171H 30 mg, TPN171H 40 mg Group, TPN171H 40 mg, TPN171H 50 mg Group, TPN171H 50 mg
Vigonvita Life Sciences
Healthy Subjects
12/22
12/22
NCT04146285: A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

Recruiting
1
15
RoW
BAT4406F
Bio-Thera Solutions
Neuromyelitis Optica Spectrum Disorders
03/23
06/23
NCT06033742: A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects

Completed
1
84
RoW
HS-10374 tablets, HS-10374-matched placebo tablets
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Psoriasis
03/23
03/23
NCT05511870: A Study of Etripamil in Healthy Subjects

Completed
1
12
RoW
Etripamil Nasal Spray 70mg, Placebo
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd., Milestone Pharmaceuticals Inc.
Healthy Chinese Subjects
03/23
03/23
NCT04534582: Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects

Completed
1
252
RoW
HLX14, EU-Prolia®, US-Prolia®, CN-Prolia®
Shanghai Henlius Biotech
Healthy Male Volunteers
09/23
09/23
NCT05694221: Drug Drug Interaction (DDI) Between Supaglutide and Digoxin or Metformin

Completed
1
34
RoW
Supaglutide injection, Diabegone, Digoxin, Digoxin Tablets, Metformin, Glucophage
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd., Huashan Hospital
Healthy Volunteers
06/23
08/23
NCT06089733: A Clinical Trial to Evaluate the Effect of Itraconazole and Rifampicin on ABSK021

Completed
1
32
RoW
Part A ABSK201 and Itraconazole, Part A ABSK201 and Rifampicin
Abbisko Therapeutics Co, Ltd
Healthy Subjects
08/23
09/23
NCT05932459: A Study to Evaluate the Bioavailability, Food Effect and Pharmacokinetics of Deuremidevir Hydrobromide for Suspension

Completed
1
38
RoW
Deuremidevir Hydrobromide for Suspension 100mg, VV116, Deuremidevir Hydrobromide for Suspension 300mg, Deuremidevir Hydrobromide for Suspension 25mg, Deuremidevir Hydrobromide tablets 100mg
Vigonvita Life Sciences
Healthy Subjects
09/23
09/23
NCT06144710: SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus

Recruiting
1
48
RoW
SG301 SC Injection, SG301 SC Placebo
Hangzhou Sumgen Biotech Co., Ltd.
Systemic Lupus Erythematosus (SLE)
05/25
10/25
NCT05907382: Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects

Recruiting
1
80
RoW
JMKX003002 will be administered orally, JMKX003002, Placebo in Cohorts 1 to 5, Matching placebo will be administered orally, Placebo in 2 Cohorts
Jemincare
Safety and Tolerability
12/23
03/24
SGB-9768-002, NCT06501573: A Study of SGB-9768 in Adult Healthy Volunteers

Not yet recruiting
1
37
NA
SGB-9768, Placebo
Suzhou Sanegene Bio Inc.
Healthy Volunteer
05/25
10/25
NCT06055777: Study of the Safety, Tolerability, and PK of SZEY-2108 Administered Intravenously to HVs in SAD and MAD Cohorts

Terminated
1
64
RoW
SZEY-2108 for injetion, Novel monocyclic β-lactam antibiotics, Placebo, 0.9% Sodium Chloride Injection
Suzhou Erye Pharmaceutical Co., Ltd.
Infections
05/24
05/24
NCT06549309: Trial of JMKX003801 in Healthy Participants

Recruiting
1
70
RoW
JMKX003801, Placebo
Jemincare
Healthy
05/25
06/25
NCT05843422: A First-in-Human Study of QY211 Gel in Adult Subjects

Recruiting
1
56
RoW
0.1% QY211 Gel or placebo, 0.3% QY211 Gel or placebo, 0.8% QY211 Gel or placebo, 1.5% QY211 Gel or placebo
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Atopic Dermatitis
10/24
10/24
NCT06111547: A Study of TAK-279 in Healthy Chinese Adults

Completed
1
24
RoW
TAK-279, Placebo
Takeda
Healthy Volunteers
07/24
08/24
NCT06827457: A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci120 in Healthy Adults.

Recruiting
1
56
RoW
GenSci120, Placebo
Changchun GeneScience Pharmaceutical Co., Ltd.
Autoimmune Disease
01/26
04/26
NCT06945445: Study of SLN12140 in Healthy Adult Participants

Not yet recruiting
1
56
RoW
SLN12140, Placebo
Linno Pharmaceuticals, Inc.
Healthy Volunteer
05/26
06/26
AACRC, NCT06342440: Early Detection of Advanced Adenomas and Colorectal Cancer

Recruiting
N/A
2000
Europe, Japan, US, RoW
DENEB, DENEB (DEtection of colorectal NEoplasias in Blood)
City of Hope Medical Center
Colorectal Cancer, Colorectal Neoplasms, Colorectal Polyp, Colorectal Adenocarcinoma, Colorectal Disorders, Colorectal Dysplasia, Colorectal Cancer Stage I, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Colorectal Cancer Stage IV, Colorectal Neoplasms Malignant, Colorectal Serrated Adenocarcinoma, Colorectal Adenoma With Severe Dysplasia, Colorectal Adenoma With Mild Dysplasia, Colorectal Adenoma With Moderate Dysplasia, Colorectal Adenoma and Carcinoma 1, Colorectal Adenomatous Polyp, Colorectal Adenocarcinoma Metastatic in the Liver
12/25
12/25
DILI-P, NCT02961413: A Prospective Cohort Study on Drug-induced Liver Injury in China（）

Recruiting
N/A
10000
RoW
Drug Induced Liver Disease Study Group
Drug-induced Liver Injury
12/30
12/30
NCT04152967: New Designed ePTFE Valved Conduits for Surgical Reconstruction of Right-ventricular Outflow Tract

Recruiting
N/A
200
RoW
new-designed PTFE valved conduits, Bovine jugular vein valved conduits
Children's Hospital of Fudan University, Shanghai Zhongshan Hospital, Shanghai Children's Medical Center
Right Ventricular Outflow Tract Absent, Congenital Heart Disease, Pulmonary Valve Disorders
12/21
11/22
NCT03959709: Pre-pectoral Versus Sub-pectoral Implant Placement in Immediate Breast Reconstruction

Recruiting
N/A
56
Canada
immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement., Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement
Ottawa Hospital Research Institute
Mastectomy, Breast Cancer
12/22
12/23
NCT05532345: Discrimination of DILI and AIH by Artificial Intelligence

Completed
N/A
2583
RoW
Beijing Friendship Hospital
Drug-induced Liver Injury, Autoimmune Hepatitis
05/23
05/23
NCT06206590: Analysis of Differential Proteins and Maternal Influencing Factors of Septic Shock in Neonates

Recruiting
N/A
116
RoW
Whole-proteomic assay
Guangdong Women and Children Hospital
Neonatal Disease
09/25
12/25
NCT05782881: High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program

Recruiting
N/A
16000
RoW
phone calls and encouraging patients' lifestyle change and medication adherence, Statin, Angiotensin-converting enzyme inhibitor, Angiotensin receptor neprilysin inhibitor, Glucagon-like peptide-1, Sodium-dependent glucose transporters 2
Wuhan Union Hospital, China, Peking University First Hospital
Cardiovascular Diseases, Diabetes Mellitus, Type 2, Coronary Disease
12/23
12/24
CNAVS, NCT06192238: China National Study of Adrenal Venous Sampling

Not yet recruiting
N/A
1500
RoW
adrenal venous sampling
Chinese Academy of Medical Sciences, Fuwai Hospital
Hyperaldosteronism
12/26
12/26
NCT06364462: Precise Evaluation Criteria for Histological Regression of NASH Fibrosis

Not yet recruiting
N/A
220
NA
lifestyle intervention
Beijing Friendship Hospital
NASH, Liver Fibrosis
03/27
04/27
NCT06773221: The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis

Not yet recruiting
N/A
195
RoW
Chiglitazar 64mg, Placebo
Beijing Friendship Hospital, Beijing Ditan Hospital, Peking University People's Hospital, Beijing YouAn Hospital
Metabolic Dysfunction Associated Fatty Liver Disease, Compensated Liver Cirrhosis
01/28
06/28
NCT04963374: the Effectiveness of Different Risk Scales In Predicting VTE in Respiratory Inpatients

Completed
N/A
100
RoW
risk evolution scale
Peking University Third Hospital
Venous Thromboembolism
12/22
12/22
Wang, Hongyu
NCT04387201: GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response

Completed
4
23
US
Cyanocobalamin, Vitamin B12, Dulaglutide, Trulicity
The University of Texas Health Science Center, Houston, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Glucose Intolerance, Overweight and Obesity, Drug Effect, Adiposity
10/23
10/23
NCT05638399: Denosumab vs Zoledronate After Lumbar Fusion

Recruiting
3
100
RoW
Denosumab 60 mg/ml [Prolia], Denosumab 6 month/subcutaneous, Zoledronate, Zoledronic acid
Shenzhen People's Hospital
Osteopenia, Lumbar Spondylolisthesis
02/23
02/23
NCT05106517: Denosumab vs Zoledronic Acid and Osteoporotic Compression Fracture

Recruiting
2/3
122
RoW
Denosumab, Denosumab 6 month/subcutaneous, Zoledronic acid, Zoledronic acid intravenous once a year
Shenzhen People's Hospital
Denosumab vs Zoledronate
03/23
03/23
NCT05065164: Denosumab and Screw Fixation for Osteoporotic Compression Fracture

Withdrawn
2/3
125
RoW
Denosumab Only Product, Denosumab
Shenzhen People's Hospital
Denosumab Allergy
03/23
09/23
ORIENT, NCT05401071: Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)

Recruiting
2/3
2442
RoW
Short Regimen with Rifapentine 10mg/kg, Standardized Regimen, Short Regimen with Rifapentine 15mg/kg, Short Regimen with Rifapentine 20mg/kg
Huashan Hospital
Tuberculosis, Pulmonary
10/24
11/27
NCT05330806: Collagenase Chemonucleolysis vs Percutaneous Endoscopic Lumbar Discectomy (PELD) for Lumbar Disc Herniation

Recruiting
N/A
140
RoW
Collagenase chemonucleolysis, Percutaneous endoscopic lumbar discectomy (PELD), Percutaneous transforaminal endoscopic discectomy (PTED) for L1-L4 and percutaneous endoscopic interlaminar discectomy(PEID) for L5-S1 lumbar disc herniation
Shenzhen People's Hospital
Lumbar Disc Herniation
06/23
06/23
NCT05655442: Arthroscopic Partial Meniscectomy Time Window

Withdrawn
N/A
90
NA
early APM, delayed APM
Shenzhen People's Hospital
Meniscus Lesion
07/23
08/23
NCT05662358: Denosumab vs Alendronate After Vertebroplasty

Recruiting
N/A
90
RoW
Denosumab, Denosumab 6 month/subcutaneous, Alendronate, oral alendronate, Placebo
Shenzhen People's Hospital
Denosumab Allergy
09/23
10/23
EndoFIND, NCT04013204: Endothelial Function Guided Therapy in Patients With Non-obstructive Coronary Artery Disease

Recruiting
N/A
1000
RoW
Endothelial function guided therapy
Peking University, Mayo Clinic, Peking University Shougang Hospital
Non-obstructive Coronary Artery Disease
12/23
06/24
NCT05965128: Promotion and Application of a New Three-level Etiological Diagnosis Strategy for Fever Clinics in Respiratory Infectious Diseases

Recruiting
N/A
1255
RoW
Huashan Hospital
Respiratory Infectious Diseases
12/23
12/27
ARGH, NCT06228248: Antibiotics Resistance Gene in Healthcare Workers

Completed
N/A
250
RoW
metagenomics
First Affiliated Hospital of Zhejiang University
Multidrug Resistant Bacterial Infection
10/24
11/24
MASS, NCT06114784: Microbiome and Host Susceptibility in Severe Pneumonia, a Prospective, Multicenter, Cohort Study

Recruiting
N/A
2000
RoW
Metagenomics
First Affiliated Hospital of Zhejiang University
Severe Pneumonia
12/25
12/25
ESAR, NCT04955756: Early Identification and Severity Prediction of Acute Respiratory Infectious Disease

Recruiting
N/A
440
RoW
mNGS, Multiplex PCR
Huashan Hospital
Acute Respiratory Infection, Severe Pneumonia, Next Generation Sequencing, Multiplex PCR
12/24
12/24
Zou, Hejian
NCT05983445: Safety & Efffficacy of Genakumab in Patients With Frequent Flares

Completed
3
313
RoW
genakumab, • Gensci048, placebo for Diprospan, placebo for genakumab, Diprospan
Changchun GeneScience Pharmaceutical Co., Ltd.
Acute Gout Arthritis
04/24
04/24
NCT06169891: A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Not yet recruiting
3
500
NA
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg, SSGJ-613 200 mg, Placebo, 0.9% sodium chloride injection, Compound Betamethasone Injection, PBO
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Acute Gout
12/24
11/25
NCT06640257: A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis

Recruiting
3
200
RoW
SHR-1314 injection, Placebo
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Psoriatic Arthritis
04/26
06/26
NCT06716606: A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Recruiting
3
225
RoW
Belimumab
GlaxoSmithKline, ICON plc
Bronchial Diseases
07/28
01/30
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Hourglass Jan 2021 - Jun 2021 : Submission in combination with rituximab for SLE
Recruiting
2/3
300
Europe, Japan, US, RoW
Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo
GlaxoSmithKline
Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
05/27
07/27
RESOLUTION-1, NCT05516758: A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

Completed
2
491
Europe, Canada, Japan, US, RoW
Peresolimab, Placebo
Eli Lilly and Company
Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases
11/23
01/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zhang, Wenhong
HS-10234-401, NCT06743438: Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB

Active, not recruiting
4
640
RoW
Tenofovir Amibufenamide（TMF）, HS-10234
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Hepatitis B, Chronic
06/24
09/29
TB-TRUST, NCT03867136: Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)

Completed
4
354
RoW
PZA sensitivity guided ultra-short all Oral Regimen, Standardized Shorter Regimen
Huashan Hospital
Multidrug Resistant Tuberculosis
08/24
08/24
NCT04201808: Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides

Recruiting
4
100
RoW
Tenofovir Alafenamide 25 MG, Vemlidy
New Discovery LLC, Beijing Ditan Hospital
Hepatitis B, Chronic
09/23
09/23
SWIFT, NCT06153069: Subclinical TB With Innovative Modified Short-course Regimens

Active, not recruiting
4
556
RoW
Short-course regimen, Standard regimen
Huashan Hospital
Tuberculosis
10/25
11/27
NCT05279235: Efficacy and Safety of JT001 (VV116) Compared With Favipiravir

Terminated
3
290
RoW
JT001, VV116, JT001 placebo, VV116 placebo, Favipiravir, Favipiravir placebo
Shanghai Vinnerna Biosciences Co., Ltd., Sponsor GmbH
Moderate to Severe COVID-19
12/22
12/22
CURE-SepSIRS, NCT05391789: Clinical Efficacy of Ulinastatin for Treatment of Sepsis With Systemic Inflammatory Response Syndrome

Not yet recruiting
3
120
RoW
Ulinastatin, Treatment, Placebo, Control
Huashan Hospital
Sepsis
06/23
12/23
ZX-7101A-207, NCT06099873: Study to Assess the Safety and Efficacy of ZX-7101A in Adolescents with Influenza

Completed
3
361
RoW
ZX-7101A, Placebo
Nanjing Zenshine Pharmaceuticals
Respiratory Viral Infection
02/25
02/25
INSPIRE-TB, NCT05081401: Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis

Recruiting
3
1050
RoW
Bdq(Lzd)+Lfx(Mfx)+Cfz(Cs)+Pto+E+H+Z, A1, A2a, A2b, A2c, A3, A4, A5, B-SOC, B1
Huashan Hospital
Multidrug Resistant Tuberculosis, Rifampicin Resistant Tuberculosis, Pre-XDR-TB
12/26
12/27
TB-YOUTH, NCT06022146: TB YOUTH - TB SYstemic Management Using One-month, Ultra-short TPT Regimen for ScHool Contacts

Recruiting
3
2978
RoW
Rifampin and Isoniazid, isoniazid and rifapentine
Huashan Hospital
Tuberculosis, Latent Tuberculosis
09/26
09/26
INSPIRE-CODA, NCT06081361: Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

Active, not recruiting
3
186
RoW
Bedaquiline, BDQ, Delamanid, DLM, Contezolid, CZD, Levofloxacin, LFX, Moxifloxacin, MFX, Clofazimine, CFZ, Linezolid, LZD, Cycloserine, CS, Prothionamide, Pto, Pyrazinamide, PZA, Para-Aminosalicylic Acid, PAS, Ethambutol, EMB
Beijing Chest Hospital, National Medical Center for Infectious Diseases
Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
10/26
12/26
NCT05242042: JT001 (VV116) for the Early Treatment of COVID-19

Terminated
2/3
381
RoW
JT001, VV116, Placebo
Shanghai JunTop Biosciences Co., LTD, Sponsor GmbH
Mild to Moderate COVID-19
03/23
03/23
ORIENT, NCT05401071: Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)

Recruiting
2/3
2442
RoW
Short Regimen with Rifapentine 10mg/kg, Standardized Regimen, Short Regimen with Rifapentine 15mg/kg, Short Regimen with Rifapentine 20mg/kg
Huashan Hospital
Tuberculosis, Pulmonary
10/24
11/27
NCT05445934: Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)

Recruiting
2/3
1188
RoW
FB2001, DC402234, FB2001 placebo
Frontier Biotechnologies Inc.
COVID-19
11/23
12/23
B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Recruiting
2
280
Europe, Canada, Japan, US, RoW
Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo
GlaxoSmithKline
Chronic Hepatitis B Virus Infection, Hepatitis B
10/27
10/27
NCT05217732: Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers

Completed
1
66
RoW
ZX-7101A, Placebo
Nanjing Zenshine Pharmaceuticals
Safety Issues, Tolerance, Pharmacokinetics, Food Effect
08/22
12/22
NCT04883177: Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101)

Completed
N/A
1000
RoW
Hepatopancreatobiliary Surgery Institute of Gansu Province, LanZhou University, Huashan Hospital, The Sixth People's Hospital of Shenyang City, Xingtai City People's Hospital, Jinchang Central Hospital, Baoding People's Hospital, The Third People's Hospital of Zhenjiang City, Shanxi Bethune Hospital, Wuhan Jinyintan Hospital, Jincheng People's Hospital, The Third People's Hospital of Tibet Autonomous Region, People's Hospital of Ningxia Hui Autonomous Region, Fuling Central Hospital of Chongqing City, Hospital of the Chengdu Office of the People's Government of Tibet Autonomous Region, The Central Hospital of Lishui City, The Third People's Hospital of Linfen City, Yibin First People's Hospital, Jingzhou Central Hospital, Wuxi Fifth People's Hospital, Qingyang People's Hospital, The First Affiliated Hospital of Anhui Medical University, Beilun Hospital of Traditional Chinese Medicine, Henan Provincial People's Hospital, Qingdao Sixth People's Hospital, The First Affiliated Hospital of Xiamen University, Shandong Provincial Hospital, Beijing YouAn Hospital, The First People's Hospital of Taicang, The Third People's Hospital of Taiyuan, Tianjin Second People's Hospital, Tianjin Third Central Hospital, Qishan Hospital of Yantai City, Affiliated Hospital of Yunnan University, The First People's Hospital of Yunnan, The Fourth Affiliated Hospital of Zhejiang University, Third Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital of Chongqing Medical University
COVID-19, Liver Disease, Vaccine Reaction
01/22
05/22
AI-MIRID, NCT06553911: Exploring the Application Efficacy of Artificial Intelligence (AI) Diagnostic Tools in Medical Imaging (MI) of Respiratory(R) Infectious (I) Disease (D)

Recruiting
N/A
2000
RoW
Artificial Intelligence-based medical imaging interpretation
Huashan Hospital
Respiratory Infectious Diseases, Artificial Intelligence, Medical Imaging
12/25
12/26
NMCIDCHESS2201, NCT05204602: Safety and Immunogenicity of COVID-19 Vaccine Booster in Patients With Liver Diseases

Recruiting
N/A
1000
RoW
Huashan Hospital, LanZhou University, Xingtai People's Hospital, The Third Central Hospital of Tianjin, The Third People's Hospital of Taiyuan, Lishui Country People's Hospital, Baoding People's Hospital, The Affiliated Hospital of Qingdao University, Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine, The Fifth People's Hospital of Wuxi, Jincheng People's Hospital, The Sixth Peoples Hospital of Shenyang, Zhenjiang Third Hospital, The Third People's Hospital of Linfen City, The First Affiliated Hospital of Dalian Medical University, The Fourth People's Hospital of Qinghai Province, The Third People's Hospital of Tibet Autonomous Region, The Second Affiliated Hospital of Chongqing Medical University, Peking University Health Science Center, The Affiliated Hospital Of Southwest Medical University
COVID-19, Vaccine Reaction, Liver Diseases
08/22
12/22
TB-TRUSTplus, NCT04717908: Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS

Completed
N/A
89
RoW
Bedaquiline, BDQ, Pyrazinamide, PZA, Linezolid, LZD, Cycloserine, Cs, Clofazimine, CFZ
Huashan Hospital
Multidrug Resistant Tuberculosis
06/24
06/24
STAT, NCT05906459: Simplification and Test and Treat Strategies Towards Hepatitis C Eliminationplatform" in China

Recruiting
N/A
20000
RoW
Anti-HCV antibody and HCV core antigen testing
Huashan Hospital
Hepatitis C Virus Infection
12/23
06/24
NCT05855395: The Standard of Care Combined With Glucocorticoid in Elderly People With Mild or Moderate COVID-19

Recruiting
N/A
5815
RoW
Glucocorticoid, dexamethasone, prednisone, methylprednisolone
Huashan Hospital
COVID-19
05/24
12/24
NCT04020536: Real World Study of Classic Infectious Disease

Recruiting
N/A
10000
RoW
Antibiotics
Huashan Hospital, First Affiliated Hospital of Xinjiang Medical University, First Affiliated Hospital of Harbin Medical University, The ninth Hospital of NanChang city, Luoyang Central Hospital, Second Affiliated Hospital of Nanchang University, The Fifth Affiliated Hospital Xinjiang Medical University, LanZhou University, Huizhou Municipal Central Hospital, First Affiliated Hospital of Fujian Medical University, Fuzhou Municipal Infectious Diseases Hospital, Henan Provincial People's Hospital, The First Affiliated Hospital of Lanzhou Medical University, Linyi People's Hospital, Nantong University, Nanyang Central Hospital, Qilu Hospital of Shandong University, Qianfoshan Hospital, Infectious Hospital of Jining City, The Affiliated Hospital of Jining Medical University and Zaozhuang City, The First Affiliated Hospital of Shanxi Medical University, First Affiliated Hospital Xi'an Jiaotong University, People's Hospital of Xinjiang Uygur Autonomous Region, Yuncheng Central Hospital, Zibo Central Hospital, The Second Affiliated Hospital of Henan Medical University, West Hospital of the First Affiliated Hospital of Guangxi University, First Affiliated Hospital of Jilin University, The Affiliated Hospital of Xuzhou Medical University, The First Affiliated Hospital with Nanjing Medical University, The First Affiliated Hospital of Anhui Medical University, The Second Hospital of Shandong University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Brucelloses, Epidemic Hemorrhagic Fever, Kala-Azar
06/24
06/29
NCT04025944: Real World Study of Chronic Viral Hepatitis

Recruiting
N/A
10000
RoW
Huashan Hospital
Hepatitis, Chronic
08/24
08/29
GRACE-TB, NCT03604848: NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB

Not yet recruiting
N/A
488
RoW
WHO-approved MDR-TB regimen, NGS-guided regimen: Regimen A, NGS-guided regimen: Regimen B, NGS-guided regimen: Regimen C
Huashan Hospital
Multidrug Resistant Tuberculosis
08/24
08/24
ESAR, NCT04955756: Early Identification and Severity Prediction of Acute Respiratory Infectious Disease

Recruiting
N/A
440
RoW
mNGS, Multiplex PCR
Huashan Hospital
Acute Respiratory Infection, Severe Pneumonia, Next Generation Sequencing, Multiplex PCR
12/24
12/24
NCT05912010: A Study on Pathogenic Surveillance and Nasopharyngeal Carriage of Children and Adolescents Based on Hospitals and Communities in Hainan Province

Recruiting
N/A
6000
RoW
NP/OP swab
Huashan Hospital
Pneumonia
12/24
12/24
RISE, NCT06597682: Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction

Not yet recruiting
N/A
632
RoW
Prednisone, Budesonide/Formoterol, Vitamin C combined with Coenzyme Q10 oral treatment, Montelukast tablets oral treatment
Huashan Hospital
Post-acute Sequelae of SARS-COV-2 Infection
07/27
07/27
NCT06923280: Sequential PEG-IFN for HBV After Ending RNA-targeted Regimens

Not yet recruiting
N/A
30
RoW
Pegylated Interferon-alpha (IFN)
Huashan Hospital
Hepatitis B, Chronic
12/27
05/28
NCT06033807: Active Screening of Latent Tuberculosis Infection in School Contacts of Active Tuberculosis Patients

Recruiting
N/A
31440
RoW
QuantiFERON-TB Gold (QFT) test, Chest CT Scan, Chest X-ray Scan, Sputum Culture, Sputum Xpert MTB/RIF
Huashan Hospital, Guizhou Center for Disease Control and Prevention
Tuberculosis, Latent Tuberculosis Infection
09/25
12/25
NCT05937178: Real-world Study Optimizing Nucleotide-analogues

Recruiting
N/A
20000
RoW
ETV/TAF/TDF/TMF/IFN, ETV/TAF/TDF/TMF
Huashan Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, Beijing YouAn Hospital, Peking University People's Hospital, Peking University First Hospital, Xiamen Hospital of Traditional Chinese Medicine, First Affiliated Hospital of Fujian Medical University, LanZhou University, Third Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, The Affiliated Hospital Of Guizhou Medical University, Hainan General Hospital, Hebei Medical University Third Hospital, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Henan Provincial People's Hospital, The Second Affiliated Hospital of Harbin Medical University, Tongji Hospital, Wuhan Union Hospital, China, Renmin Hospital of Wuhan University, Central South University, Xiangya Hospital of Central South University, The First Hospital of Jilin University, the Second Hospital of Nangjing, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Hospital of Xuzhou Medical University, The First Affiliated Hospital of Nanchang University, Shengjing Hospital, Qingdao Sixth People's Hospital, Shandong Provincial Hospital Affiliated to Shandong First Medical University, The Second Hospital of Shandong University, The First Affiliated Hospital of Shanxi Medical University, Tang-Du Hospital, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, West China Hospital, Tianjin Second People's Hospital, First Affiliated Hospital of Xinjiang Medical University, The First People's Hospital of Yunnan, Shulan (Hangzhou) Hospital, Zhejiang University, Southwest Hospital, China, The Second Affiliated Hospital of Chongqing Medical University, Sichuan Provincial People's Hospital
Hepatitis B, Chronic
01/29
01/29
NCT05965388: Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy

Not yet recruiting
N/A
5000
RoW
nucleoside analogues or interferon
Wen-hong Zhang, Shandong Provincial Hospital Affiliated to Shandong First Medical University, First Affiliated Hospital Xi'an Jiaotong University, The Affiliated Hospital of Xuzhou Medical University, First Affiliated Hospital of Fujian Medical University, The Third People's Hospital of Taiyuan, The First People's Hospital of Yunnan, The First Affiliated Hospital of Anhui Medical University, Wuhan Union Hospital, China, The First Affiliated Hospital with Nanjing Medical University
HBV, HCC
02/29
02/29
TCCT, NCT04484129: MDR-TB Close Contacts Tracing in China ( Study)

Not yet recruiting
N/A
500
RoW
Huashan Hospital
Multidrug Resistant Tuberculosis
12/22
12/22
NCT05493917: A Real-world Study to Evaluate the Safety and Immunogenicity of a Third-dose Booster After Two Doses of an Inactivated COVID-19 Vaccine

Recruiting
N/A
2000
RoW
an inactivated SARS-CoV-2 vaccine named BBIBP-CorV
Huashan Hospital
COVID-19, Vaccine Reaction
12/22
12/22
OASIS, NCT04896255: Long-term Outcomes of Anti-viral Therapies in Patients With Chronic Viral Hepatitis B

Recruiting
N/A
20000
RoW
peginterferon alpha based regimen, nucleos(t)ide
Huashan Hospital, Chinese Foundation for Hepatitis Prevention and Control, Taiyuan No.3 Hospital, First Affiliated Hospital of Chongqing Medical University, Beijing YouAn Hospital, Henan Provincial People's Hospital, Yunnan Provincial No.1 Hospital, Third Affiliated Hospital, Sun Yat-Sen University, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of Xiamen University, Beijing Ditan Hospital, Tianjing No.2 People's Hospital, Qingdao No.6 People's Hospital, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Ningbo Beilun District Traditional Chinese Medicine Hospital, Wuxi No.5 People's Hospital, Taicang No.1 People's hospital, First Affiliated Hospital Xi'an Jiaotong University
Chronic Hepatitis b
07/25
07/30
Zhang, Jing
NCT05536726: A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants with Moderate-to-Severe Plaque Psoriasis

Completed
3
458
RoW
608 Q2W, 608 Q4W, Placebo, PBO
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Psoriasis
10/23
06/24
NCT05213507: Inhaled Amikacin in Preventing AECOPD

Not yet recruiting
3
136
RoW
aerosol inhaled Amikacin Sulfate Injection, Aerosol Inhaled investigation drug, conventional therapy, Comparison Group
Shanghai Zhongshan Hospital
COPD, COPD Exacerbation
12/23
12/23
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Recruiting
3
522
RoW
D-1553 Tablet, Docetaxel injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non Small Cell Lung Cancer
10/26
12/27
ReNEW, NCT06373731: Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

Recruiting
3
360
Europe, US, RoW
Elamipretide, Elamipretide HCL, Placebo
Stealth BioTherapeutics Inc.
Age Related Macular Degeneration (ARMD)
08/26
08/27
ZX-7101A-207, NCT06099873: Study to Assess the Safety and Efficacy of ZX-7101A in Adolescents with Influenza

Completed
3
361
RoW
ZX-7101A, Placebo
Nanjing Zenshine Pharmaceuticals
Respiratory Viral Infection
02/25
02/25
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NAC Attack, NCT05537220: Oral N-acetylcysteine for Retinitis Pigmentosa

Recruiting
3
438
Europe, Canada, US, RoW
N-acetylcysteine, Placebo
Johns Hopkins University, National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Centro Medico ABC, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania
Retinitis Pigmentosa
12/28
12/28
NCT06569524: Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)

Recruiting
2
120
RoW
TQA2225/AP025 or TQA2225/AP025 Placebo 25mg, TQA2225/AP025 or TQA2225/AP025 Placebo 50mg
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Non-alcoholic Steatohepatitis
12/26
12/27
PRO-CHASE, NCT05419193: PROpranolol for Cerebral Hemorrhage-ASsociated pnEumonia

Completed
2
168
RoW
Propranolol Hydrochloride, control group
Beijing Tiantan Hospital
Stroke, Vascular Accident, Intracranial Hemorrhages, Intracerebral Hemorrhage, Hemorrhagic Stroke, Stroke, Acute
12/24
03/25
TEASE, NCT02402660: Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Enrolling by invitation
2
160
US
ALK-001, C20-D3-Retinyl Acetate, C20 Deuterated vitamin A, Placebo
Alkeus Pharmaceuticals, Inc.
Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
06/26
11/26
NCT05328531: Clinical Study of Genakumab for Injection in Patients With Acute Gout

Completed
1/2
121
RoW
Genakumab for Injection, Placebo for Genakumab for Injection
Changchun GeneScience Pharmaceutical Co., Ltd., Huashan Hospital, Hainan General Hospital, Linyi People's Hospital, The Second Affiliated Hospital of Chongqing Medical University, Changhai Hospital, The First Affiliated Hospital with Nanjing Medical University, Shengjing Hospital, Affiliated Hospital of Nantong University
Acute Gout
06/22
06/22
NCT06302374: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults

Completed
1/2
202
RoW
GR2001, Placebo, HTIG, Tetanus Toxoid
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Tetanus
11/23
02/24
NCT04434482: IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer

Completed
1/2
59
US, RoW
IMP4297(senaparib), temozolomide
Impact Therapeutics, Inc.
Advanced Solid Tumours, Small Cell Lung Cancer
04/24
04/24
NCT04361812: Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection

Not yet recruiting
1
60
RoW
HS632, Recombinant anti IgE humanized monoclonal antibody 150mg, Omalizumab (Xolair®), Omalizumab 150mg
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd
Similarity of Pharmacokinetics and Safety
12/21
12/21
NCT05280483: ABSK021 Food Effect Study in Healthy Subjects

Completed
1
16
RoW
ABSK021 with fed state, ABSK021 with fasted state
Abbisko Therapeutics Co, Ltd
Neoplasms
08/22
05/23
NCT04880512: The Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy Subjects

Recruiting
1
102
RoW
SYHX 1901 tablets, Placebo
CSPC Ouyi Pharmaceutical Co., Ltd.
Healthy Subjects
08/22
12/22
NCT05217732: Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers

Completed
1
66
RoW
ZX-7101A, Placebo
Nanjing Zenshine Pharmaceuticals
Safety Issues, Tolerance, Pharmacokinetics, Food Effect
08/22
12/22
NCT05490316: A Study of IBI353 (Orismilast) in Chinese Healthy Adults

Completed
1
20
RoW
IBI353 (Orismilast), placebo
Innovent Biologics (Suzhou) Co. Ltd.
Healthy Subjects
11/22
12/22
NCT04994912: First in Human Study of EI-001 Monoclonal Antibody in Healthy Volunteers

Recruiting
1
36
RoW
EI-001, Placebo
Elixiron Immunotherapeutics Limited
Healthy
02/25
04/25
NCT05750355: Evaluate the Effect of TPN171H on the QT/QTc Interval in Healthy Volunteers

Completed
1
32
RoW
TPN171H 10 mg Group, TPN171H 10 mg, TPN171H 30 mg Group, TPN171H 30 mg, TPN171H 40 mg Group, TPN171H 40 mg, TPN171H 50 mg Group, TPN171H 50 mg
Vigonvita Life Sciences
Healthy Subjects
12/22
12/22
NCT04146285: A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

Recruiting
1
15
RoW
BAT4406F
Bio-Thera Solutions
Neuromyelitis Optica Spectrum Disorders
03/23
06/23
NCT06033742: A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects

Completed
1
84
RoW
HS-10374 tablets, HS-10374-matched placebo tablets
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Psoriasis
03/23
03/23
NCT05511870: A Study of Etripamil in Healthy Subjects

Completed
1
12
RoW
Etripamil Nasal Spray 70mg, Placebo
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd., Milestone Pharmaceuticals Inc.
Healthy Chinese Subjects
03/23
03/23
NCT04534582: Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects

Completed
1
252
RoW
HLX14, EU-Prolia®, US-Prolia®, CN-Prolia®
Shanghai Henlius Biotech
Healthy Male Volunteers
09/23
09/23
NCT05694221: Drug Drug Interaction (DDI) Between Supaglutide and Digoxin or Metformin

Completed
1
34
RoW
Supaglutide injection, Diabegone, Digoxin, Digoxin Tablets, Metformin, Glucophage
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd., Huashan Hospital
Healthy Volunteers
06/23
08/23
NCT06089733: A Clinical Trial to Evaluate the Effect of Itraconazole and Rifampicin on ABSK021

Completed
1
32
RoW
Part A ABSK201 and Itraconazole, Part A ABSK201 and Rifampicin
Abbisko Therapeutics Co, Ltd
Healthy Subjects
08/23
09/23
NCT05932459: A Study to Evaluate the Bioavailability, Food Effect and Pharmacokinetics of Deuremidevir Hydrobromide for Suspension

Completed
1
38
RoW
Deuremidevir Hydrobromide for Suspension 100mg, VV116, Deuremidevir Hydrobromide for Suspension 300mg, Deuremidevir Hydrobromide for Suspension 25mg, Deuremidevir Hydrobromide tablets 100mg
Vigonvita Life Sciences
Healthy Subjects
09/23
09/23
NCT06144710: SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus

Recruiting
1
48
RoW
SG301 SC Injection, SG301 SC Placebo
Hangzhou Sumgen Biotech Co., Ltd.
Systemic Lupus Erythematosus (SLE)
05/25
10/25
NCT05907382: Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects

Recruiting
1
80
RoW
JMKX003002 will be administered orally, JMKX003002, Placebo in Cohorts 1 to 5, Matching placebo will be administered orally, Placebo in 2 Cohorts
Jemincare
Safety and Tolerability
12/23
03/24
SGB-9768-002, NCT06501573: A Study of SGB-9768 in Adult Healthy Volunteers

Not yet recruiting
1
37
NA
SGB-9768, Placebo
Suzhou Sanegene Bio Inc.
Healthy Volunteer
05/25
10/25
NCT06055777: Study of the Safety, Tolerability, and PK of SZEY-2108 Administered Intravenously to HVs in SAD and MAD Cohorts

Terminated
1
64
RoW
SZEY-2108 for injetion, Novel monocyclic β-lactam antibiotics, Placebo, 0.9% Sodium Chloride Injection
Suzhou Erye Pharmaceutical Co., Ltd.
Infections
05/24
05/24
NCT06549309: Trial of JMKX003801 in Healthy Participants

Recruiting
1
70
RoW
JMKX003801, Placebo
Jemincare
Healthy
05/25
06/25
NCT05843422: A First-in-Human Study of QY211 Gel in Adult Subjects

Recruiting
1
56
RoW
0.1% QY211 Gel or placebo, 0.3% QY211 Gel or placebo, 0.8% QY211 Gel or placebo, 1.5% QY211 Gel or placebo
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Atopic Dermatitis
10/24
10/24
NCT06111547: A Study of TAK-279 in Healthy Chinese Adults

Completed
1
24
RoW
TAK-279, Placebo
Takeda
Healthy Volunteers
07/24
08/24
NCT06827457: A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci120 in Healthy Adults.

Recruiting
1
56
RoW
GenSci120, Placebo
Changchun GeneScience Pharmaceutical Co., Ltd.
Autoimmune Disease
01/26
04/26
NCT06945445: Study of SLN12140 in Healthy Adult Participants

Not yet recruiting
1
56
RoW
SLN12140, Placebo
Linno Pharmaceuticals, Inc.
Healthy Volunteer
05/26
06/26
AACRC, NCT06342440: Early Detection of Advanced Adenomas and Colorectal Cancer

Recruiting
N/A
2000
Europe, Japan, US, RoW
DENEB, DENEB (DEtection of colorectal NEoplasias in Blood)
City of Hope Medical Center
Colorectal Cancer, Colorectal Neoplasms, Colorectal Polyp, Colorectal Adenocarcinoma, Colorectal Disorders, Colorectal Dysplasia, Colorectal Cancer Stage I, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Colorectal Cancer Stage IV, Colorectal Neoplasms Malignant, Colorectal Serrated Adenocarcinoma, Colorectal Adenoma With Severe Dysplasia, Colorectal Adenoma With Mild Dysplasia, Colorectal Adenoma With Moderate Dysplasia, Colorectal Adenoma and Carcinoma 1, Colorectal Adenomatous Polyp, Colorectal Adenocarcinoma Metastatic in the Liver
12/25
12/25
DILI-P, NCT02961413: A Prospective Cohort Study on Drug-induced Liver Injury in China（）

Recruiting
N/A
10000
RoW
Drug Induced Liver Disease Study Group
Drug-induced Liver Injury
12/30
12/30
NCT04152967: New Designed ePTFE Valved Conduits for Surgical Reconstruction of Right-ventricular Outflow Tract

Recruiting
N/A
200
RoW
new-designed PTFE valved conduits, Bovine jugular vein valved conduits
Children's Hospital of Fudan University, Shanghai Zhongshan Hospital, Shanghai Children's Medical Center
Right Ventricular Outflow Tract Absent, Congenital Heart Disease, Pulmonary Valve Disorders
12/21
11/22
NCT03959709: Pre-pectoral Versus Sub-pectoral Implant Placement in Immediate Breast Reconstruction

Recruiting
N/A
56
Canada
immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement., Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement
Ottawa Hospital Research Institute
Mastectomy, Breast Cancer
12/22
12/23
NCT05532345: Discrimination of DILI and AIH by Artificial Intelligence

Completed
N/A
2583
RoW
Beijing Friendship Hospital
Drug-induced Liver Injury, Autoimmune Hepatitis
05/23
05/23
NCT06206590: Analysis of Differential Proteins and Maternal Influencing Factors of Septic Shock in Neonates

Recruiting
N/A
116
RoW
Whole-proteomic assay
Guangdong Women and Children Hospital
Neonatal Disease
09/25
12/25
NCT05782881: High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program

Recruiting
N/A
16000
RoW
phone calls and encouraging patients' lifestyle change and medication adherence, Statin, Angiotensin-converting enzyme inhibitor, Angiotensin receptor neprilysin inhibitor, Glucagon-like peptide-1, Sodium-dependent glucose transporters 2
Wuhan Union Hospital, China, Peking University First Hospital
Cardiovascular Diseases, Diabetes Mellitus, Type 2, Coronary Disease
12/23
12/24
CNAVS, NCT06192238: China National Study of Adrenal Venous Sampling

Not yet recruiting
N/A
1500
RoW
adrenal venous sampling
Chinese Academy of Medical Sciences, Fuwai Hospital
Hyperaldosteronism
12/26
12/26
NCT06364462: Precise Evaluation Criteria for Histological Regression of NASH Fibrosis

Not yet recruiting
N/A
220
NA
lifestyle intervention
Beijing Friendship Hospital
NASH, Liver Fibrosis
03/27
04/27
NCT06773221: The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis

Not yet recruiting
N/A
195
RoW
Chiglitazar 64mg, Placebo
Beijing Friendship Hospital, Beijing Ditan Hospital, Peking University People's Hospital, Beijing YouAn Hospital
Metabolic Dysfunction Associated Fatty Liver Disease, Compensated Liver Cirrhosis
01/28
06/28
NCT04963374: the Effectiveness of Different Risk Scales In Predicting VTE in Respiratory Inpatients

Completed
N/A
100
RoW
risk evolution scale
Peking University Third Hospital
Venous Thromboembolism
12/22
12/22
Wang, Hongyu
NCT04387201: GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response

Completed
4
23
US
Cyanocobalamin, Vitamin B12, Dulaglutide, Trulicity
The University of Texas Health Science Center, Houston, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Glucose Intolerance, Overweight and Obesity, Drug Effect, Adiposity
10/23
10/23
NCT05638399: Denosumab vs Zoledronate After Lumbar Fusion

Recruiting
3
100
RoW
Denosumab 60 mg/ml [Prolia], Denosumab 6 month/subcutaneous, Zoledronate, Zoledronic acid
Shenzhen People's Hospital
Osteopenia, Lumbar Spondylolisthesis
02/23
02/23
NCT05106517: Denosumab vs Zoledronic Acid and Osteoporotic Compression Fracture

Recruiting
2/3
122
RoW
Denosumab, Denosumab 6 month/subcutaneous, Zoledronic acid, Zoledronic acid intravenous once a year
Shenzhen People's Hospital
Denosumab vs Zoledronate
03/23
03/23
NCT05065164: Denosumab and Screw Fixation for Osteoporotic Compression Fracture

Withdrawn
2/3
125
RoW
Denosumab Only Product, Denosumab
Shenzhen People's Hospital
Denosumab Allergy
03/23
09/23
ORIENT, NCT05401071: Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)

Recruiting
2/3
2442
RoW
Short Regimen with Rifapentine 10mg/kg, Standardized Regimen, Short Regimen with Rifapentine 15mg/kg, Short Regimen with Rifapentine 20mg/kg
Huashan Hospital
Tuberculosis, Pulmonary
10/24
11/27
NCT05330806: Collagenase Chemonucleolysis vs Percutaneous Endoscopic Lumbar Discectomy (PELD) for Lumbar Disc Herniation

Recruiting
N/A
140
RoW
Collagenase chemonucleolysis, Percutaneous endoscopic lumbar discectomy (PELD), Percutaneous transforaminal endoscopic discectomy (PTED) for L1-L4 and percutaneous endoscopic interlaminar discectomy(PEID) for L5-S1 lumbar disc herniation
Shenzhen People's Hospital
Lumbar Disc Herniation
06/23
06/23
NCT05655442: Arthroscopic Partial Meniscectomy Time Window

Withdrawn
N/A
90
NA
early APM, delayed APM
Shenzhen People's Hospital
Meniscus Lesion
07/23
08/23
NCT05662358: Denosumab vs Alendronate After Vertebroplasty

Recruiting
N/A
90
RoW
Denosumab, Denosumab 6 month/subcutaneous, Alendronate, oral alendronate, Placebo
Shenzhen People's Hospital
Denosumab Allergy
09/23
10/23
EndoFIND, NCT04013204: Endothelial Function Guided Therapy in Patients With Non-obstructive Coronary Artery Disease

Recruiting
N/A
1000
RoW
Endothelial function guided therapy
Peking University, Mayo Clinic, Peking University Shougang Hospital
Non-obstructive Coronary Artery Disease
12/23
06/24
NCT05965128: Promotion and Application of a New Three-level Etiological Diagnosis Strategy for Fever Clinics in Respiratory Infectious Diseases

Recruiting
N/A
1255
RoW
Huashan Hospital
Respiratory Infectious Diseases
12/23
12/27
ARGH, NCT06228248: Antibiotics Resistance Gene in Healthcare Workers

Completed
N/A
250
RoW
metagenomics
First Affiliated Hospital of Zhejiang University
Multidrug Resistant Bacterial Infection
10/24
11/24
MASS, NCT06114784: Microbiome and Host Susceptibility in Severe Pneumonia, a Prospective, Multicenter, Cohort Study

Recruiting
N/A
2000
RoW
Metagenomics
First Affiliated Hospital of Zhejiang University
Severe Pneumonia
12/25
12/25
ESAR, NCT04955756: Early Identification and Severity Prediction of Acute Respiratory Infectious Disease

Recruiting
N/A
440
RoW
mNGS, Multiplex PCR
Huashan Hospital
Acute Respiratory Infection, Severe Pneumonia, Next Generation Sequencing, Multiplex PCR
12/24
12/24
Zou, Hejian
NCT05983445: Safety & Efffficacy of Genakumab in Patients With Frequent Flares

Completed
3
313
RoW
genakumab, • Gensci048, placebo for Diprospan, placebo for genakumab, Diprospan
Changchun GeneScience Pharmaceutical Co., Ltd.
Acute Gout Arthritis
04/24
04/24
NCT06169891: A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Not yet recruiting
3
500
NA
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg, SSGJ-613 200 mg, Placebo, 0.9% sodium chloride injection, Compound Betamethasone Injection, PBO
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Acute Gout
12/24
11/25
NCT06640257: A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis

Recruiting
3
200
RoW
SHR-1314 injection, Placebo
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Psoriatic Arthritis
04/26
06/26
NCT06716606: A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Recruiting
3
225
RoW
Belimumab
GlaxoSmithKline, ICON plc
Bronchial Diseases
07/28
01/30
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Hourglass Jan 2021 - Jun 2021 : Submission in combination with rituximab for SLE
Recruiting
2/3
300
Europe, Japan, US, RoW
Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo
GlaxoSmithKline
Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
05/27
07/27
RESOLUTION-1, NCT05516758: A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

Completed
2
491
Europe, Canada, Japan, US, RoW
Peresolimab, Placebo
Eli Lilly and Company
Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases
11/23
01/25
 

Download Options